about
The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler.Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.Inhalable tranexamic acid for haemoptysis treatment.The formulation of a pressurized metered dose inhaler containing theophylline for inhalation.Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability.Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations.Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers.Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler.Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery.Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs.Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia.Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles.Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model.Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide.Autophagy and airway fibrosis: Is there a link?
P50
Q35064978-EB2AAD96-7118-4053-96F5-B63344D30684Q35617445-99CFF787-D492-4E21-8A3C-22E8E5EEE55AQ35621138-4FF129AE-14EB-433F-A27B-324FB8EB14E6Q35625546-74B9F63F-4F83-49D1-B197-E5D94AF7A0E1Q35874313-F96361E7-DABE-4F24-BB00-AA09736A08DBQ38212420-36C74360-BBB2-42DC-81EC-51E1DFCFE227Q38816463-3E4ED36C-6CAA-4337-A3A6-29584485C936Q38925706-43667DD2-EF59-48E8-9D5B-DB31342B5B78Q39022790-5EFD9251-1217-494F-824F-7CED4CB0F949Q39135769-A22758F1-7CFC-48CE-9F79-8DED4E3108B6Q39173695-30212450-6969-43EB-9F9D-3D94D0B2B88BQ39195090-507E3CB9-A300-4D9F-AFC5-F8C4375331FCQ39350900-E2BC98DB-48B9-4D09-8779-DD1C9F01AF1FQ39421517-A517BFE1-CE35-4BA0-8CB0-3368353DD6ACQ39717640-4A9C6C1D-8745-4514-9663-E3B1D6E2A6CCQ40765897-242C81F6-29D1-4B25-A3FA-78A33D1BF634Q42289683-E602A2E6-CDFB-471C-BBEA-08738808A9AE
P50
name
Mehra Haghi
@en
Mehra Haghi
@nl
type
label
Mehra Haghi
@en
Mehra Haghi
@nl
prefLabel
Mehra Haghi
@en
Mehra Haghi
@nl